title: Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient.
abstract: The oncological treatment for advanced stage head and neck cancer is based on a combination of cisplatin and cetuximab, and radiotherapy. However, very few data are available on this multimodal approach for this type of cancer in pancreas and renal recipients. We report the case of a pancreas and renal recipient being treated with combined chemoradiotherapy for a locally advanced squamous cancer of the larynx. The patient was under treatment with ciclosporin-based immunosuppressive therapy at the time of cancer diagnosis, which was then replaced by everolimus. After 4 years of follow-up, the patients is still free from disease, with a local complete response, only mild residual dysphonia, and with edema of the chin. Cetuximab plus radiation could be an adequate option for cancer treatment in solid organ transplant recipients affected by locally advanced head and neck cancer; the concomitant use of mammalian target of rapamycin pathway inhibitors may have a synergistic effect in enhancing tumor control in these patients; however, further dedicated studies are warranted.
authors.affiliation: aRadiotherapy Department, ASST Cremona bUnit of Molecular Therapy and Pharmacogenomics, ASST Cremona cDepartment of Molecular and Translational Medicine, Section of Pharmacology and University Center DIFF-Drug Innovation Forward Future, University of Brescia, Brescia dDepartment of Medical, Surgery, and Health Sciences, University of Trieste, Piazza Ospitale 1, Trieste, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Bonetta
authors.forename: Laura
authors.initials: L
authors.lastname: Bandera
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.forename: Ines
authors.initials: I
authors.lastname: Cafaro
authors.forename: Alberto
authors.initials: A
authors.lastname: Bottini
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D006801:Humans; D016030:Kidney Transplantation; D007822:Laryngeal Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy*; D016035:Pancreas Transplantation
chemical_list: D000970:Antineoplastic Agents; D000068818:Cetuximab